The stock of PDS Biotechnology Corporation (PDSB) has seen a -3.57% decrease in the past week, with a 14.08% gain in the past month, and a 16.55% flourish in the past quarter. The volatility ratio for the week is 5.38%, and the volatility levels for the past 30 days are at 5.61% for PDSB. The simple moving average for the past 20 days is 1.69% for PDSB’s stock, with a -18.09% simple moving average for the past 200 days.
Is It Worth Investing in PDS Biotechnology Corporation (NASDAQ: PDSB) Right Now?
Moreover, the 36-month beta value for PDSB is 1.26. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PDSB is 43.98M and currently, short sellers hold a 6.60% of that float. On June 18, 2025, PDSB’s average trading volume was 472.90K shares.
PDSB) stock’s latest price update
PDS Biotechnology Corporation (NASDAQ: PDSB)’s stock price has plunge by -8.99relation to previous closing price of 1.78. Nevertheless, the company has seen a -3.57% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-09 that Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe
Analysts’ Opinion of PDSB
Many brokerage firms have already submitted their reports for PDSB stocks, with B. Riley Securities repeating the rating for PDSB by listing it as a “Buy.” The predicted price for PDSB in the upcoming period, according to B. Riley Securities is $10 based on the research report published on November 01, 2022 of the previous year 2022.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see PDSB reach a price target of $25. The rating they have provided for PDSB stocks is “Overweight” according to the report published on June 28th, 2021.
H.C. Wainwright gave a rating of “Buy” to PDSB, setting the target price at $6 in the report published on November 10th of the previous year.
PDSB Trading at 19.33% from the 50-Day Moving Average
After a stumble in the market that brought PDSB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.35% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PDSB starting from Freitag Gregory Gene, who purchase 15,060 shares at the price of $1.66 back on Feb 28 ’25. After this action, Freitag Gregory Gene now owns 61,213 shares of PDS Biotechnology Corporation, valued at $25,000 using the latest closing price.
Glover Stephen C., the Director of PDS Biotechnology Corporation, purchase 15,061 shares at $1.66 during a trade that took place back on Feb 28 ’25, which means that Glover Stephen C. is holding 78,851 shares at $25,001 based on the most recent closing price.
Stock Fundamentals for PDSB
The total capital return value is set at -1.23. Equity return is now at value -119.22, with -61.18 for asset returns.
Based on PDS Biotechnology Corporation (PDSB), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at -1.8. The debt to equity ratio resting at 0.85. The interest coverage ratio of the stock is -7.98.
Currently, EBITDA for the company is -33.75 million with net debt to EBITDA at 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.33.
Conclusion
To wrap up, the performance of PDS Biotechnology Corporation (PDSB) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
